167 related articles for article (PubMed ID: 30502650)
1. Reduction of non-specific toxicity of immunotoxin by intein mediated reconstitution on target cells.
Wang J; Han L; Chen J; Xie Y; Jiang H; Zhu J
Int Immunopharmacol; 2019 Jan; 66():288-295. PubMed ID: 30502650
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
3. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
[TBL] [Abstract][Full Text] [Related]
4. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
Jiao P; Zhang J; Dong Y; Wei D; Ren Y
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
[TBL] [Abstract][Full Text] [Related]
5. Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.
Kornberger P; Skerra A
MAbs; 2014; 6(2):354-66. PubMed ID: 24492291
[TBL] [Abstract][Full Text] [Related]
6. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
7. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
[TBL] [Abstract][Full Text] [Related]
8. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
9. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
Boyer CM; Pusztai L; Wiener JR; Xu FJ; Dean GS; Bast BS; O'Briant KC; Greenwald M; DeSombre KA; Bast RC
Int J Cancer; 1999 Aug; 82(4):525-31. PubMed ID: 10404066
[TBL] [Abstract][Full Text] [Related]
10. A general purification platform for toxic proteins based on intein trans-splicing.
Shi C; Tarimala A; Meng Q; Wood DW
Appl Microbiol Biotechnol; 2014 Nov; 98(22):9425-35. PubMed ID: 25296714
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of a novel fibroblast growth factor receptor targeted immunotoxin on a human ovarian teratocarcinoma cell line.
Zhang H; Zhang S; Zhuang H; Lu F
Cancer Biother Radiopharm; 2006 Aug; 21(4):321-32. PubMed ID: 16999598
[TBL] [Abstract][Full Text] [Related]
12. A streamlined method for preparing split intein for NMR study.
Lee YZ; Lee YT; Lin YJ; Chen YJ; Sue SC
Protein Expr Purif; 2014 Jul; 99():106-12. PubMed ID: 24751877
[TBL] [Abstract][Full Text] [Related]
13. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
[TBL] [Abstract][Full Text] [Related]
14. Conserved residues that modulate protein trans-splicing of Npu DnaE split intein.
Wu Q; Gao Z; Wei Y; Ma G; Zheng Y; Dong Y; Liu Y
Biochem J; 2014 Jul; 461(2):247-55. PubMed ID: 24758175
[TBL] [Abstract][Full Text] [Related]
15. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells.
Lv X; Zhang J; Xu R; Dong Y; Sun A; Shen Y; Wei D
Appl Microbiol Biotechnol; 2016 Jul; 100(14):6403-6413. PubMed ID: 27063011
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
17. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
18. A new design immunotoxin for killing high-grade glioma U87 cells: from in vitro to in vivo.
Luqiu Z; Yiquan K; Gengqiang L; Yijing L; Xiaodan J; Yingqian C
J Immunotoxicol; 2012; 9(4):353-8. PubMed ID: 22458328
[TBL] [Abstract][Full Text] [Related]
19. Protein immobilization on liposomes and lipid-coated nanoparticles by protein trans-splicing.
Chu NK; Olschewski D; Seidel R; Winklhofer KF; Tatzelt J; Engelhard M; Becker CF
J Pept Sci; 2010 Oct; 16(10):582-8. PubMed ID: 20862726
[TBL] [Abstract][Full Text] [Related]
20. Traceless splicing enabled by substrate-induced activation of the Nostoc punctiforme Npu DnaE intein after mutation of a catalytic cysteine to serine.
Cheriyan M; Chan SH; Perler F
J Mol Biol; 2014 Dec; 426(24):4018-4029. PubMed ID: 25451033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
